Target Level for Hemoglobin Correction in Patients With Diabetes and CKD: Primary Results of the Anemia Correction in Diabetes (ACORD) Study

摘要: Background Patients with diabetes and anemia are at high risk of cardiovascular disease. The Anemia CORrection in Diabetes (ACORD) Study aimed to investigate the effect correction on cardiac structure, function, outcomes patients early diabetic nephropathy. Methods One hundred seventy-two type 1 or 2 mellitus, mild moderate anemia, stage 3 chronic kidney disease were randomly assigned attain a target hemoglobin (Hb) level either 13 15 g/dL (130 150 g/L; group 1) 10.5 11.5 (105 115 2). primary end point was change left ventricular mass index (LVMI). Secondary points included echocardiographic variables, renal quality life, safety. Results Median Hb LVMI similar groups (Hb, 11.9 11.7 [119 117 g/L]; LVMI, 113.5 112.3 g/m , respectively). At study end, levels 13.5 (135 g/L) 12.1 (121 ( P ; 2, 116.5 ). Multivariate analysis showed nonsignificant decrease = 0.15) versus 2. had no rate creatinine clearance, but resulted significantly improved life 0.04). There clinically relevant differences adverse events between groups. Conclusion In hypertrophy, an does not LVMI. However, normalization prevented additional increase safe, life.